DNA Script Wins the Grand Prize Trophy at the 2022 French Future Unicorns Ceremony
DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, won the Grand Prize Trophy at the 2022 Future Unicorns Awards, whose ceremony took place on September 15, 2022, at the Bourrienne Hotel (Paris). Of the 1400 French companies initially identified for consideration, a jury narrowed them down to 250 that met the criteria, from which DNA Script was selected as the Grand Prize winner.
"DNA Script is honored to receive the Grand Prize Trophy, which recognizes our business and innovation strategy. Biology holds such incredible promise to solve some of mankind’s biggest challenges, with applications not just across healthcare but also climate change, food and clean water supply, bio-engineered materials and environmentally friendly chemicals, DNA data storage, and so much more. DNA Script’s mission is to make it easy for researchers to print DNA to accelerate this scientific discovery and the coming bio-revolution,” said Xavier Godron, DNA Script co-founder and CTO, in accepting the award on behalf of the company and his co-founders Thomas Ybert, CEO, and Sylvain Gariel, COO. “We share this award with the entire DNA Script team, who invest in the company's success daily; with our investors, who have placed their trust in us since the company’s inception; and with our customers, who share our vision to accelerate discovery through direct access to in-house DNA printing. We thank the members of the jury as well as their partners Audacia, Caisse d'Epargne, Deloitte, Emlyon Business School, Euronext, Reputation Age and Scope Group for this distinction."
DNA Script won the Biotech and Medtech Future Unicorns Award in 2021, and since then has achieved several milestones. These include completing a $200 million Series C investment round and expanding its global presence in China, Hong Kong, India, Singapore, South Korea and Taiwan for the sale, distribution and support of its products through distribution agreements. Following the launch of the SYNTAX System, the first commercial product using Enzymatic DNA Synthesis targeted at genomics and molecular biology workflows, in 2021, the company continues to develop their technology and portfolio of products to address DNA supply bottlenecks in life science research, precision therapeutics, biodefense, clinical testing and DNA data storage. The company launched new products earlier this year that enable researchers to develop much more efficiently new diagnostic or research assays, for instance in infectious diseases, personalized oncology fields or spatial biology. Recently the company announced a continued collaboration with the French Defense Innovation Agency, in liaison with the French Armament General Directorate (DGA), to detect and diagnose new pathogens. This collaboration followed a disclosed partnership with Wellcome Leap to accelerate the development of RNA-based products, including messenger RNA vaccines.
The Future Unicorns Trophies aim to identify French companies with strong growth potential that in the next five years can be valued at more than €1 billion. Five sectors are studied, and seven prizes are awarded: BioTech and MedTech, e-Commerce and Advertising, GreenTech and Mobility, Industry 4.0 and SaaS, and AI and Big Data. The selected companies must meet various criteria, including having their headquarters in France, being <15 years old, having raised >€5 million since company inception and being an unlisted independent company, among others.
About DNA Script
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005403/en/
Contact information
DNA Script Contact
Joleen Rau
joleen.rau@dnascript.co
publicrelations@dnascript.co
Press Contacts in the US
Seismic
Valerie Enes
415-692-6799
valerie@teamseismic.com
Press Contact in Europe
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verimatrix: Signing of an Agreement for the Sale of XTD Assets (Code and Application Protection) to Guardsquare8.12.2025 18:45:00 EET | Press release
Regulatory News: VERIMATRIX (Euronext Paris: VMX, FR0010291245), a leading provider of user security solutions for a safer connected world, announces the signing of an agreement with Belgium-based Guardsquare, the leading provider of mobile application security, for the sale of its Extended Threat Defense (XTD) assets. Guardsquare, the creators of the open-source optimization tool, ProGuard, offers the most complete mobile application security platform on the market spanning automated testing and multi-layered protection, real time threat monitoring, and app attestation. Guardsquare’s 975+ customers are located in more than 95 countries and represent all major industries. Launched in 2021, Verimatrix's Extended Threat Defence (XTD) business is composed of a group of cybersecurity experts specialised in protecting mobile, web and desktop applications. Using a range of innovative solutions, XTD solutions predict, detect and respond to threats before their targets are compromised. Over th
WNBA Champion Sabrina Ionescu Becomes Global Brand Ambassador for Ant International8.12.2025 18:00:00 EET | Press release
Four-time WNBA All-Star Sabrina Ionescu today becomes a new Global Brand Ambassador for Ant International, a leading global provider of digital payments, digitisation, and financial technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208536426/en/ The partnership is built on a shared commitment to creating a more inclusive and sustainable world through empowering underserved communities and youth groups with sports and technology innovation. It marks an important step in Ant International’s journey to foster growth and expand access to financial tools through innovative technology. Ionescu serves as the first Ant International global brand ambassador from North America. “Sabrina embodies the spirit of perseverance and the passion for excellence that is driving young talents and small businesses around the world to uplift their communities,” said Douglas Feagin, President of Ant International. “As a legend in a spor
SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer8.12.2025 17:20:00 EET | Press release
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker innovation, announced today the presentation of seven studies at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2025, held December 9–12 in San Antonio, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208979141/en/ These abstracts showcase the growing clinical utility and innovation of the company’s proprietary RNA platform and underscore REVEAL GENOMICS’ commitment to improving outcomes for individuals with breast cancer. Across all studies, REVEAL GENOMICS and its collaborators analyzed more than 1,300 tumor samples from individuals with HER2-positive, ER-negative, and triple-negative breast cancer—one of the most extensive genomic contributions to SABCS 2025. Seven independent studies validate the performance and clinical impact of REVEAL GENOMICS’ precision oncology platform New HER2
NetApp Advances EMEA & LATAM Presence with Appointment of Willem Hendrickx as Customer Demand for AI Accelerates8.12.2025 17:15:00 EET | Press release
NetApp (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the appointment of Willem Hendrickxas Senior Vice President and General Manager, EMEA & LATAM, effective January 5, 2026. Hendrickxwill lead NetApp’s business strategy, go-to-market execution, and partner engagement across Europe, the Middle East, Africa, and Latin America. Reporting to NetApp President César Cernuda, Hendrickx brings a deep regional knowledge and track record of building high-performing teams, further enabling the acceleration of NetApp’s international footprint by helping global customers navigate the evolving demands of hybrid cloud and AI-driven data infrastructure. Hendrickx holds a Master’s degree in Applied Economics from KU Leuven and is based in Brussels, Belgium. “Willem joins NetApp at a pivotal time as customer demand surges for intelligent, AI-driven, cloud-enabled data infrastructure globally,” said César Cernuda, President, NetApp. “This appointment underscores our commit
MediaKind and Harmonic’s Video Business to Combine, Creating a Leading Streaming-Infrastructure Platform8.12.2025 16:37:00 EET | Press release
MediaKind, a global leader in cloud-based video streaming technology, today announced it has entered into an agreement to acquire the Video Business of Harmonic Inc. (NASDAQ: HLIT) for approximately $145 million. Following a French employee works council consultation process, the parties would immediately execute a purchase agreement, and the transaction would be expected to close in the first half of 2026, subject to customary regulatory approvals and closing conditions. The transaction creates a world-class independent SaaS streaming infrastructure provider by combining two established video technology organizations with complementary strengths in SaaS streaming, appliance platforms, and cloud AV workloads. The combined company will serve a blue-chip customer base, generate more than $100 million in annual recurring revenue (ARR), over $150 million in annual appliance revenue, and, as a business 100% focused on video, create an enhanced foundation for long-term growth. Additionally,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom